This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial
by Zacks Equity Research
Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial are part of the Zacks top Analyst Blog.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
5 Safe Stocks to Buy as SVB Collapse Shakes Wall Street
by Nalak Das
At this stage, it will be prudent to stay with safe stocks.Five such stocks are: CAH, CINF, CLX, KO and GIS.
After Plunging -10.82% in 4 Weeks, Here's Why the Trend Might Reverse for Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cardinal Health (CAH) Stock Moves -0.14%: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $71.19, moving -0.14% from the previous trading session.
Cardinal Health's (CAH) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
Cardinal Health's (CAH) latest partnership is expected to improve patients' healthcare journey by offering a more integrated experience that connects all sites of care.
3 Reasons Growth Investors Will Love Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Is Trending Stock Cardinal Health, Inc. (CAH) a Buy Now?
by Zacks Equity Research
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
IDEXX (IDXX) Global Sales, Instrument Placement Robust
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.
Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.
NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.
Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.
Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y
by Zacks Equity Research
Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.
Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.
Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails
by Zacks Equity Research
Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.
Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.
Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.
Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up
by Zacks Equity Research
Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.
Medtronic (MDT) Receives CE Mark Approval For Aurora System
by Zacks Equity Research
Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.
Reasons to Retain Patterson Companies (PDCO) Stock Now
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.